HSP90B2P and prostate carcinoma: A large amount of literature has associated HSPs, both experimentally and clinically, with initiation and progression of prostate cancer (Ratajczak et al., 2022; Fu et al., 2022; Saini and Sharma, 2018) and suggested that effective interventions targeting HSP members with either molecular inhibitors or genetic methods are expected to become a novel therapeutic regimen (Fu et al., 2022; Saini and Sharma, 2018).